Cargando…
Introduction to managing patients with recurrent ovarian cancer
Ovarian cancer is the 5th most common cancer found in women in the UK. It is the leading cause of death from gynaecological cancer, and is the 4th most common cause of cancer death among UK women. Similar to the majority of other cancers, relative survival rates for ovarian cancer are improving, alt...
Autor principal: | Gabra, Hani |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683381/ https://www.ncbi.nlm.nih.gov/pubmed/26759525 http://dx.doi.org/10.1016/S1359-6349(15)70003-0 |
Ejemplares similares
-
Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management
por: Rumford, Megan, et al.
Publicado: (2020) -
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer
por: Sharma, Rohini, et al.
Publicado: (2011) -
Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
por: Rizzuto, Ivana, et al.
Publicado: (2015) -
OPCML, a novel systems regulator of tyrosine kinase signaling in ovarian and other cancers
por: Gabra, H
Publicado: (2012) -
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
por: Sharma, R, et al.
Publicado: (2009)